Literature DB >> 17828814

CD4+ T cell responses in hepatitis C virus infection.

Nasser Semmo1, Paul Klenerman.   

Abstract

Hepatitis C virus (HCV) infection is a major cause of liver damage, with virus-induced end-stage disease such as liver cirrhosis and hepatocellular carcinoma resulting in a high rate of morbidity and mortality worldwide. Evidence that CD4+ T cell responses to HCV play an important role in the outcome of acute infection has been shown in several studies. However, the mechanisms behind viral persistence and the failure of CD4+ T cell responses to contain virus are poorly understood. During chronic HCV infection, HCV-specific CD4+ T cell responses are relatively weak or absent whereas in resolved infection these responses are vigorous and multispecific. Persons with a T-helper type I profile, which promotes cellular effector mechanisms are thought to be more likely to experience viral clearance, but the overall role of these cells in the immunopathogenesis of chronic liver disease is not known. To define this, much more data is required on the function and specificity of virus-specific CD4+ T cells, especially in the early phases of acute disease and in the liver during chronic infection. The role and possible mechanisms of action of CD4+ T cell responses in determining the outcome of acute and chronic HCV infection will be discussed in this review.

Entities:  

Mesh:

Year:  2007        PMID: 17828814      PMCID: PMC4611761          DOI: 10.3748/wjg.v13.i36.4831

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  70 in total

1.  Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Authors:  Thorsten U Vogel; Thomas C Friedrich; David H O'Connor; William Rehrauer; Elizabeth J Dodds; Heather Hickman; William Hildebrand; John Sidney; Alessandro Sette; Austin Hughes; Helen Horton; Kathy Vielhuber; Richard Rudersdorf; Ivna P De Souza; Matthew R Reynolds; Todd M Allen; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels.

Authors:  F Bolacchi; A Sinistro; C Ciaprini; F Demin; M Capozzi; F C Carducci; C M J Drapeau; G Rocchi; A Bergamini
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 3.  Regulatory T cells in virus infections.

Authors:  Barry T Rouse; Pranita P Sarangi; Susmit Suvas
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

4.  Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.

Authors:  Georg M Lauer; Tam N Nguyen; Cheryl L Day; Gregory K Robbins; Theresa Flynn; Katherine McGowan; Eric S Rosenberg; Michaela Lucas; Paul Klenerman; Raymond T Chung; Bruce D Walker
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  HLA class II genes determine the natural variance of hepatitis C viral load.

Authors:  L J Fanning; J Levis; E Kenny-Walsh; M Whelton; K O'Sullivan; F Shanahan
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

6.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection.

Authors:  Anne M Wertheimer; Camette Miner; David M Lewinsohn; Anna W Sasaki; Ezra Kaufman; Hugo R Rosen
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

8.  Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection.

Authors:  N Semmo; G Krashias; C Willberg; P Klenerman
Journal:  J Viral Hepat       Date:  2007-07       Impact factor: 3.728

9.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.

Authors:  H M Diepolder; R Zachoval; R M Hoffmann; E A Wierenga; T Santantonio; M C Jung; D Eichenlaub; G R Pape
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  25 in total

1.  Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.

Authors:  María Q Marín; Patricia Pérez; Karl Ljungberg; Carlos Óscar S Sorzano; Carmen E Gómez; Peter Liljeström; Mariano Esteban; Juan García-Arriaza
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

2.  Hepatic immunopathology during occult hepacivirus re-infection.

Authors:  Cordelia Manickam; Amanda J Martinot; Rhianna A Jones; Valerie Varner; R Keith Reeves
Journal:  Virology       Date:  2017-09-13       Impact factor: 3.616

3.  Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis.

Authors:  H I Basha; V Subramanian; A Seetharam; D S Nath; S Ramachandran; C D Anderson; S Shenoy; W C Chapman; J S Crippin; T Mohanakumar
Journal:  Am J Transplant       Date:  2011-04       Impact factor: 8.086

4.  Modulation of IL-2 expression after uptake of hepatitis C virus non-enveloped capsid-like particles: the role of p38 kinase.

Authors:  Elisavet Serti; Polyxeni P Doumba; George Thyphronitis; Panagiota Tsitoura; Konstantina Katsarou; Pelagia Foka; Manousos M Konstandoulakis; John Koskinas; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

5.  A mouse model for hepatitis C virus infection: are we there yet?

Authors:  Cordelia Manickam; R Keith Reeves
Journal:  Ann Infect       Date:  2017-11-30

6.  Synthetic antigens representing the antigenic variation of human hepatitis C virus.

Authors:  Kyung Hee Kang; Yasuhiro Yamamura; Maria P Carlos; Nicolas Karvelas; In-Sup Kim; Deepa Sunkara; Rebecca Rivera; Murray B Gardner; David E Anderson; Francisco Diaz-Mitoma; José Torres; Juan P Marquez
Journal:  Viral Immunol       Date:  2010-10       Impact factor: 2.257

7.  Innate immunity defines the capacity of antiviral T cells to limit persistent infection.

Authors:  Daniel M Andrews; Marie J Estcourt; Christopher E Andoniou; Matthew E Wikstrom; Andrea Khong; Valentina Voigt; Peter Fleming; Hyacinth Tabarias; Geoffrey R Hill; Robbert G van der Most; Anthony A Scalzo; Mark J Smyth; Mariapia A Degli-Esposti
Journal:  J Exp Med       Date:  2010-05-31       Impact factor: 14.307

Review 8.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Phenotypic and functional alterations of primary human PBMCs induced by HCV non-enveloped capsid-like particles uptake.

Authors:  Polyxeni P Doumba; Elisavet Serti; Maria Boutsikou; Manousos M Konstadoulakis; Urania Georgopoulou; John Koskinas
Journal:  Cell Mol Life Sci       Date:  2013-05-05       Impact factor: 9.261

10.  TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.

Authors:  Timothy T Spear; Glenda G Callender; Jeffrey J Roszkowski; Kelly M Moxley; Patricia E Simms; Kendra C Foley; David C Murray; Gina M Scurti; Mingli Li; Justin T Thomas; Alexander Langerman; Elizabeth Garrett-Mayer; Yi Zhang; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-02-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.